Tag: ALS

BrainStorm’s NurOwn does not have enough clinical data according to FDA  

BrainStorm Cell Therapeutics announced it recently met with senior leadership from the US Food and Drug Administration (FDA) and received feedback on a high-level data summary...

Brainstorm receives US$16 million grant for Phase 3 clinical trial of...

Brainstorm Cell Therapeutics has been awarded a US$16 million grant from the California Institute for Regenerative Medicine (CIRM) to support the pivotal Phase 3...

Massachusetts General Hospital and California Pacific Medical Center to participate in...

BrainStorm Cell Therapeutics has signed definitive agreements with Massachusetts General Hospital (Boston, USA) and California Pacific Medical Center (CPMC, San Francisco, USA) to enrol...

FDA approves drug to treat ALS

The US Food and Drug Administration has approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS). Radicava is an intravenous infusion given by...

BrainStorm Cell Therapeutics’ trial of NurOwn in ALS deemed safe by...

The Data Safety and Monitoring Board has conducted its second pre-planned safety review of the phase 2 clinical trial of NurOwn in amyotrophic lateral...

Presymptomatic ALS patients consume more calories but have lower BMIs than...

Presymptomatic patients with amyotrophic lateral sclerosis (ALS) consumed more daily calories but had lower body-mass index (BMI) than those individuals without ALS, reports a...

Clinical trial moves stem cell therapy for ALS patients one step...

Stem cells are a safe therapy for patients with amyotrophic lateral sclerosis (ALS), according to the results of a recently completed phase 1 clinical trial.

NurOwn demonstrates a statistically significant effect in ALS patients

BrainStorm Cell Therapeutics presented results from its phase 2a study of NurOwn in amyotrophic lateral sclerosis (ALS) at a poster session at the American Academy of Neurology annual meeting, in Washington, DC, USA.

The ALS Association to collaborate with GlaxoSmithKline on new ALS clinical...

The ALS Association, Harvard Stem Cell Institute, and Massachusetts General Hospital Neurological Clinical Research Institute have announced that they are collaborating with GlaxoSmithKline on a clinical trial to evaluate the potential of an anti-epileptic drug in ALS patients.

ALS Association triples research spending following ice bucket donations

The ALS Association Board of Trustees has developed a long-term strategy for leveraging the Ice Bucket Challenge donations it has received to advance its integrated mission of leading the fight to treat and cure ALS through global research, care services and public policy.